Helix BioPharma Corp. is making waves on the TSX with a notable gain.
Helix BioPharma Corp. (HBP.TO) is rising today, showing a positive shift of 2.86% in its stock price. The company’s focus on advancing its oncology programs continues to attract investor interest, contributing to this upward movement.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$113.04M
52W high
$5.40
52W low
$0.98
1W change
+2.67%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 62.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+62.3% Upside
Current Price
C$1.54
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
47.4%
Annualized
90-Day Vol
64.8%
Annualized
Trend (90d)
-26.4%
Annualized drift
90d Mean
C$1.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.49 | C$1.27 – C$1.76 |
| 60 trading days | C$1.45 | C$1.15 – C$1.82 |
| 90 trading days | C$1.40 | C$1.06 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Helix BioPharma's ongoing developments in the oncology sector, as these may drive future performance and investor sentiment.
Helix BioPharma Corp. Market Cap Reaches CA$106.93 Million
With a market cap of CA$106.93 million, Helix BioPharma is positioned in a niche segment of the biotech industry, focusing on oncology treatments.
Bull case
The recent rise in stock price shows growing confidence in Helix BioPharma's oncology programs. This momentum could lead to significant advancements and potential partnerships down the line.
Bear case
Despite today’s gain, Helix BioPharma's financials are still a concern. The company has not reported a profit margin, indicating challenges in achieving profitability.
Market Performance Overview
Advertisement
In today’s trading session, Helix BioPharma Corp. has seen its stock price increase by 2.86%, closing at CA$1.44. This rise comes amid a broader interest in biotech stocks, particularly those focused on innovative treatments.
Company Focus and Future Prospects
Helix BioPharma continues to concentrate on advancing its oncology programs, which is crucial for its long-term growth strategy. Investors should watch for any upcoming announcements related to clinical trials or partnerships that could further impact the stock's performance.
Financial Health and Investor Sentiment
While the stock is performing well today, Helix BioPharma's lack of profitability raises questions about its financial sustainability. Investors should weigh the potential for growth against the inherent risks associated with investing in biotech companies.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
